Celldex Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Celldex Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Celldex Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Celldex Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Celldex Therapeutics Inc (Celldex) is a biopharmaceutical company focused on the science of mast cell biology and the development of therapeutic antibodies. These antibodies are designed to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune, and other devastating diseases. Its product pipeline includes monoclonal and bispecific antibodies aimed at treating conditions driven by mast cell activity, where current treatments are inadequate. The company focuses on harnessing the human immune system to address severe inflammatory, allergic, autoimmune, and other debilitating diseases.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Celldex's R&D arm focuses on the continued development of Barzolvolimab, a monoclonal antibody targeting the KIT receptor, which is being studied across multiple mast cell-driven diseases such as Chronic Spontaneous Urticaria, Cold Urticaria, Symptomatic Dermographism, Prurigo Nodularis, and Atopic Dermatitis. The company is also advancing its next-generation bispecific antibody platform, with CDX-622 as its first candidate targeting inflammatory diseases by neutralizing TSLP and depleting mast cells via SCF starvation. The company aims to build a fully integrated, commercial-stage biopharmaceutical company that develops therapies for patients with unmet medical needs. The R&D unit of Celldex is responsible for the discovery and development of innovative scientific programs, focusing on antibody-based immunotherapies. The unit leverages core technologies to design targeted therapeutic candidates and supports the expansion of additional candidates for inflammatory diseases through its next-generation bispecific antibody platform. In FY2025, the company spent US$245.1 million on its R&D activities, which grew 49.9% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer